First Wave BioPharma (First Wave BioPharma) Float Percentage Of Total Shares Outstanding : 97.28% (As of Apr. 29, 2024)

View and export this data going back to 2016. Start your Free Trial

What is First Wave BioPharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, First Wave BioPharma's float shares is 1.97 Mil. First Wave BioPharma's total shares outstanding is 2.03 Mil. First Wave BioPharma's float percentage of total shares outstanding is 97.28%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, First Wave BioPharma's Insider Ownership is 37.25%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, First Wave BioPharma's Institutional Ownership is 0.14%.

First Wave BioPharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

First Wave BioPharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	1.97	/	2.03
	=	97.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Wave BioPharma (First Wave BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » First Wave BioPharma Inc (NAS:FWBI) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Executives

James Sapirstein	director, officer: President and CEO	1517 SAN JACINTO, HOUSTON TX 77002
Sarah Romano	officer: Chief Financial Officer	271 WAVERLY OAKS ROAD, WALTHAM MA 02452
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
David Andrew Hoffman	director	777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431
Edward Borkowski	director	1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Alastair Riddell	director	C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226
Vern Lee Schramm	director	1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461
Gregory Oakes	director	760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
James Pennington	officer: CHIEF MEDICAL OFFICER	25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Daniel H Schneiderman	officer: CHIEF FINANCIAL OFFICER	760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Ross Edmund Burke Jr.	10 percent owner	C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196
Johan M. Spoor	director, officer: President and CEO	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Maged Shenouda	director	305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Pelican Partners Llc	10 percent owner	PO BOX 2422, WESTPORT CT 06880